Mersana Therapeutics: We’re about to learn if ADC platforms are more tolerable (MRSN)
I have a PhD in biochemistry and spent many years analyzing clinical trials and biotech companies. My passion is for everyone to understand the science behind the businesses we invest in, and my mission is to help you do your due diligence and not get caught up in the pitfalls of investing in this space.
Analysts revealed: I/we have no stock, option or similar derivatives positions in any of the companies mentioned and have no plans to initiate any such positions within the next 72 hours. This article was written by myself and expresses my own opinions. I received no compensation (other than from Seeking Alpha). I have no business relationships with any of the companies whose stock is mentioned in this article.
Seeking Alpha Disclosure: Past performance is no guarantee of future results. No advice or recommendation is given as to whether any investment is suitable for a particular investor. Any views or opinions stated above may not reflect the views of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or U.S. investment adviser or investment bank. Our analysts are third-party authors, including professional and individual investors, who may not be licensed or certified by any agency or regulatory body.
